AIM ImmunoTech announces official print of data analysis for EAP study of PDAC

AIM ImmunoTech announced the official print publication of the data analysis from a long-term Early Access Program, EAP, studying the company’s drug Ampligen for the treatment of advanced pancreatic ductal adenocarcinoma, PDAC. The manuscript titled “Rintatolimod in Advanced Pancreatic Cancer enhances Anti-Tumor Immunity through Dendritic Cell-Mediated T Cell Responses,” appears in the journal Clinical Cancer Research, one of oncology’s most prestigious journals. In addition to the published manuscript, further commentary discussing the potential of Ampligen and two other drugs, referencing findings from the journal article, were published. Key highlights from the additional commentary include: Ampligen has been found to be also safely used through a systemic route. Interesting increases in cDC1 numbers and cytokines governing T-cell activation and migration are found to be upregulated. Researchers detected an important enrichment of B-cell numbers in peripheral blood from patients treated with Ampligen. B-cells correlated with long-term survival in a previous study. AIM is currently evaluating Ampligen as a therapy for metastatic pancreatic ductal adenocarcinoma